tirzepatide and dementia versus semaglutide for the prevention of mild cognitive impairment, dementia, Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study GLP-1 weight-loss drugs may cut

Alongside Ozempic dose pen, Novo Nordisk developed Wegovy , a higher-dose injectable approved for chronic weight management

We found: Adherence with GLP-1 therapy differs for diabetics and those using the medication for weight loss

Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis

Some people use it as a bridge to establish new habits and heal insulin resistance, while others with chronic metabolic damage may stay on a maintenance dose longer

The evolution of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes mellitus